# Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response

> **NCT01128803** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nantes University Hospital** · enrollment: 1 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** injection of the cell therapy product

## Key facts

- **NCT ID:** NCT01128803
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128803, "Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response". Retrieved via MORVS 2026-11-21 from https://api.morvs.ai/clinical/NCT01128803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
